Biliary Tract Carcinoma clinical trials

Explore recruiting biliary tract carcinoma clinical trials.

Recruiting biliary tract carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Biliary Tract Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carcinoma. A non-comparative randomized phase II study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma

Ireland, Germany, Spain, Netherlands, Italy, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

TACTIC : MP0317, A TUMOR TARGETING FAP DEPENDENT CD40 AGONIST DARPIN, IN COMBINATION WITH CHEMOIMMUNOTHERAPY IN FIRST LINE TREATMENT FOR PATIENTS WITH ADVANCED BILIARY TRACT CARCINOMA A RANDOMIZED NON COMPARATIVE PROOF OF CONCEPT PHASE II STUDY

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Spain, France, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Biliary Tract Carcinoma trials by city

Biliary Tract Carcinoma clinical trials

Recruiting biliary tract carcinoma studies right now

AB122 Platform Study

Ligufalimab and Cadonilimab in Advanced Liver Cancers

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas

Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer